Frank Armstrong, M.D., Named Chief Executive Officer of Bioaccelerate Holdings Inc.

Frank Armstrong, M.D., Named Chief Executive Officer of
Bioaccelerate Holdings Inc. 


NEW YORK, April 18  /PRNewswire-FirstCall/ -- Bioaccelerate Holdings Inc.
(OTC:BACL.OB) (BULLETIN BOARD: BACL.OB) , an emerging drug development company,
announced today the appointment of Frank Armstrong, M.D., to the position of
Chief Executive Officer.  Dr. Armstrong has previously served as Chief
Operating Officer of the Company.  Lee Cole, founder, Chairman of the Board and
Chief Executive Officer, will remain Chairman.

Mr. Cole stated,  "As we advance our pipeline of drug candidates through
development and commercialization, and continue to make further investments in
promising new drug candidates and technologies where we can add significant
value, Frank's business acumen, operational capabilities and broad-based
experience in the pharmaceutical industry will be even more valuable as we
continue to drive near-term licensing and product development opportunities and
commercial success."

Dr. Armstrong joined Bioaccelerate in January 2005.  Prior to Bioaccelerate, he
served as Chief Executive Officer of Provensis, a wholly owned subsidiary of
BTG plc.  Earlier, Dr. Armstrong was Chief Executive Officer of Phoqus, a
privately held drug delivery company.  Dr. Armstrong has held senior positions
at Bayer AG and the Medical Research and Communications Group, Zeneca
Pharmaceuticals (now AstraZeneca), based in Germany and the US.

"Lee Cole has created a business model for Bioaccelerate that is designed to
streamline the development and commercialization of promising drug candidates
and rapidly add value for our shareholders, " commented Dr. Armstrong. 
"Achieving Bioaccelerate's ambitious growth objectives for 2005 and beyond is
an extremely exciting challenge and I am looking forward to working with the
entire senior management team as well as our partners to drive our success."

About Bioacclerate Holdings Inc.

Bioaccelerate Holdings Inc. (BACL.OB) is a pharmaceutical development
organization ("PDO") that seeks to acquire, develop and commercialize novel
pharmaceutical compounds in an efficient, cost-effective way.  Bioaccelerate
uses its broad network of academic, industry and capital market relationships
to expedite drug development and raise capital to create and fund its
subsidiary companies, which are organized by vertical portfolios in five
therapeutic areas: oncology, specialty pharmaceuticals, central nervous system
disorders (CNS), cardiovascular disease and anti-infectives.

Bioaccelerate conducts its business directly and through its subsidiaries. The
Company holds majority equity interests in 10 biopharmaceutical companies,
three of which are public, and holds minority interests in four
biopharmaceutical companies, two of which are public.  The Company also holds a
minority equity interest in a public nanotechnology company. Bioaccelerate's
strategy relies on its development network for research, clinical development
and project management to guide early-stage compounds from the discovery
process through to Phase II/III development where incremental value can be
created. Bioaccelerate Holdings is listed on the Over-The-Counter Bulletin
Board under the symbol "BACL.OB."  For more information on Bioaccelerate, visit
the Company's website at http://www.bioaccelerate.com/.

Bioaccelerate Safe Harbor Statement

Certain statements contained herein are "forward-looking" statements (as such
term is defined in the Private Securities Litigation Reform Act of 1995).
Because these statements include risks and uncertainties, actual results may
differ materially from those expressed or implied by such forward-looking
statements.  Specifically, factors that could cause actual results to differ
materially from those expressed or implied by such forward-looking statements
include, but are not limited to: risks associated with pre-clinical and
clinical developments in the biopharmaceutical industry in general or
Bioaccelerate's compounds under development in particular; the potential
failure of Bioaccelerate's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the early stage
of Bioaccelerate's compounds under development; failure to successfully
implement or complete clinical trials; failure to receive marketing clearance
from regulatory agencies for our compounds under development; acquisitions,
divestitures, mergers, licenses or strategic initiatives that change
Bioaccelerate's business, structure or projections; the development of
competing products; uncertainties related to Bioaccelerate's dependence on
third parties and partners; and those risks described in the filings with the
SEC, all of which are under Bioaccelerate's prior name Mobile Design Concepts,
Inc.  Bioaccelerate disclaims any obligation to update these forward-looking
statements.

   Contacts:
   Bioaccelerate Holdings Inc.
   Christopher O'Toole
   Senior Vice President
   212-332-4387

   Matthew Haines (Investors)
   Vice President
   Noonan Russo
   212-845-4235

   Emily Poe (Media)
   Vice President
   Noonan Russo
   212-845-4266


DATASOURCE: Bioaccelerate Holdings Inc.



CONTACT:  Christopher O'Toole, Senior Vice President of Bioaccelerate

Holdings Inc., [phone]; or Investors: Matthew Haines, Vice President,

[phone], or Emily Poe, Vice President, [phone], both of Noonan

Russo, both for Bioaccelerate Holdings Inc.



Web site:  http://www.bioaccelerate.com/ 

Copyright